Osilodrostat in Cushing’s disease: the management of its efficacy and the pitfalls of post-surgical results

SUMMARY: Osilodrostat is a novel, orally administered cortisol synthesis inhibitor, approved in 2020 by the European Medicines Agency (EMA) for the treatment of Cushing’s syndrome in adults. A significant amount of the studies currently available in the literature focus on treatment in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Antonini, Simone, Brunetti, Alessandro, Zampetti, Benedetta, Boeris, Davide, Saladino, Andrea, Cesare Cozzi, Renato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2022
Materias:
Novel Treatment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716402/
https://www.ncbi.nlm.nih.gov/pubmed/36515363
http://dx.doi.org/10.1530/EDM-22-0311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716402/
https://www.ncbi.nlm.nih.gov/pubmed/36515363
http://dx.doi.org/10.1530/EDM-22-0311

Ejemplares similares